ELISA/assay

Natalizumab (TYSABRI) ELISA

KBI1020

1 x 96 well

Natalizumab (TYSABRI) ELISA

Natalizumab (Tysabri) is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin used in the treatment of multiple sclerosis and Crohn’s disease. Tysabri and was previously named Antegren. Natalizumab is administered by intravenous infusion every 28 days and reduces the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Natalizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Natalizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Natalizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Natalizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

ELISA

Assay Kits

Therapeutic Drug Monitoring

1 x 96 well

Natalizumab

Natalizumab

< 2.5 ng/mL

2.5-160 ng/ml

100 uL

Serum, Plasma, Cell Culture Supernatants

2.5 hours

RUO

wet

2-8C